Instrument Inactif

Communiqués Amarantus Bioscience Holdings Inc OTC Bulletin Board

Actions

AMBS

US02300U1060

Cours en clôture OTC Bulletin Board Autres places de cotation
- ^USD	-

2022

Mise à jour sectorielle : Les valeurs financières ajoutent encore aux baisses de mercredi

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Amarantus BioScience : Notification of Late Filing	18/11/21	PU
Amarantus BioScience : Todos Medical Completes Acquisition of Breakthrough Diagnostics, Gains Full Rights to the Alzheimer’s Blood Diagnostic LymPro™ Test from Amarantus	28/07/20	AQ
Emerald Organic Products : Restructures Joint Venture Agreement With Todos Medical by Entering Joint Collaboration Agreement	08/05/20	AQ
Amarantus BioScience : Todos Medical and 3DMed Enter Into Coronavirus (COVID-19) and Influenza A/B Testing Kit Distribution Agreement in US and Israel	17/03/20	AQ
Amarantus BioScience : Announces Subsidiary MANF Therapeutics Enters Into Material Transfer Agreement with Dyadic International	06/02/20	AQ
Amarantus Releases Letter to Shareholders	04/02/20	GL
Amarantus Acquires Majority Interest in CBD Wellness Company Hempori	30/01/20	GL
Emerald Organic Products : Amarantus Completes Sublicense of ESS, MANF and PhenoGuard to Emerald Organic Products	02/01/20	AQ
Amarantus to Present at 12th Annual LD Micro Main Event	09/12/19	GL
Amarantus Subsidiary Elto Pharma Receives Notice of Allowance Covering Use of Eltoprazine Combined with CBD to Treat Parkinson’s Disease	04/12/19	GL
Amarantus Announces Issuance of Chinese Patent Covering the Use of MANF and CDNF in Retinal Disorders for Subsidiary MANF Therapeutics	21/11/19	GL
Amarantus Provides Recapitalization Update to Shareholders	18/11/19	GL
Amarantus Enters Into Agreement to License Diverse Therapeutics Portfolio to CBD-focused Emerald Organic Products	24/10/19	GL
Amarantus Bioscience : Provides Comprehensive Corporate Update	01/12/17	PR
Amarantus Bioscience : Enters Into Forbearance and Capital Restructuring Agreements With Holders of Secured Debt, Convertible Preferred Stock and Warrants	17/11/17	PR
Amarantus Bioscience : Provides Update on Restructuring Efforts and Letter of Intent with SeD Biomedical, Inc.	05/04/17	PR
Amarantus Bioscience : Completes Sale of Diagnostics Division, Announces Fiscal Year 2015 and First Quarter 2016 Financial Results	03/06/16	PR
Amarantus Bioscience : Announces Capital Infusion	21/04/16	PR
Amarantus Bioscience : Announces Cancellation of Special Meeting of Shareholders	22/03/16	PR
Amarantus Bioscience : Avant Diagnostics and Amarantus Diagnostics to Combine Operations With Theranostics Health	07/03/16	PR

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Amarantus Bioscience Holdings Inc OTC Bulletin Board

Actions

AMBS

US02300U1060

Communiqués

Filtres